Updated on 23 December 2015
Dengvaxia is the first dengue vaccine developed by Sanofi
Singapore: Sanofi Pasteur, the vaccines division of Sanofi, has recieved marketing approval in Philippines for its dengue vaccine, Dengvaxia.
The Philippines' Food and Drug Administration approved Dengvaxia, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas.
"Approval of the first dengue vaccine in Asia, which bears 70 percent of global disease burden1, is a major milestone in dengue prevention and public health," notes Mr Olivier Charmeil, president and CEO, Sanofi Pasteur.
"Prevention of dengue is an urgent and growing medical priority in the Philippines," says Dr May Book Montellano, president, Philippine Foundation for Vaccination. "Vaccination is widely accepted as one of the most cost-effective ways to reduce the spread of infectious diseases like dengue. The approval of Dengvaxia, the world's first dengue vaccine, in the Philippines will be a critical addition to the ongoing public education and vector control efforts currently directed towards dengue prevention in our country."
Dengue is a major public health priority in tropical and subtropical countries in Asia and Latin America.